Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that tofacitinib and baricitinib, when administered with unorthodox weight-stratified dosing in pediatric patients with moderate-to-severe AA, showed comparable efficacy and tolerability, though baricitinib's efficacy decreased with non-standard dosing.

This phase I study found that MK-2206 was well tolerated and demonstrated evidence of AKT signaling blockade in patients with advanced solid tumors, with the maximum-tolerated dose established at 60 mg.

This study optimized a screening assay to identify molecules that inhibit or enhance TRPM5 ion channel activity, which may have implications for treating dysfunctions linked to cardiac arrhythmias and diabetes.

The researchers reported that topical tofacitinib in mice increased hair follicles in the growth phase and boosted noggin and BMP4 mRNA expressions, compared to a vehicle and minoxidil.

This study reported that a novel nanomedicine combining berberine and sinapic acid significantly inhibited the growth of mouse mammary carcinoma cells and demonstrated an anti-tumor effect in vivo, without significant systemic toxicity after 28 days, suggesting a promising, low-toxicity therapeutic strategy for breast cancer.

In this study, GTx-027, a selective androgen receptor modulator, significantly inhibited tumor growth in certain breast cancer models and showed good tolerance in a Phase II trial with postmenopausal women.

This study found that tofacitinib led to ≥50% hair regrowth in eight out of twelve patients with moderate to severe alopecia areata, suggesting a potential benefit for using JAK inhibitors in treating this condition.

This study identified certain benzopyran derivatives with a bulky tert-butyloxycarbonylamino group as effective KATP channel openers that inhibit insulin secretion in rat pancreatic islets.

This study found that Musashi-2 regulates mRNA targets to restrict epithelial cell migration, revealing a key function of Msi2 beyond its known role in promoting cell growth.

This study in Mexican adolescents with severe alopecia areata reported that oral tofacitinib treatment resulted in hair growth and reduced alopecia severity without serious adverse effects.

In this study, encorafenib combined with binimetinib was well tolerated in melanoma patients, resulting in relatively few cutaneous adverse events compared to other BRAF and MEK inhibitors.

In this report, oral baricitinib improved both alopecia areata and immune thrombocytopenia in a 56-year-old patient, suggesting a potential dual benefit for these conditions, although regular platelet monitoring and hematology consultation are recommended.

This study found that trametinib and vemurafenib increased sebum production and gene expression related to lipid accumulation in hamster sebocytes, which may help explain certain side effects in patients.

This study found that GTx-024 significantly increased total lean body mass and improved physical function in healthy elderly men and postmenopausal women, suggesting potential use for muscle wasting conditions.

This 104-week follow-up trial found that baricitinib is effective and safe for treating severe alopecia areata but requires continuous use to sustain hair regrowth. The drug is included in the NVDV guidelines and reimbursed by Dutch insurers for this purpose.

In this study, herbal hair tonic made from Usada Bali ingredients significantly increased hair growth in mice without causing skin irritation compared to a negative control.

This study found that a community education program using group discussions and leaflets significantly increased knowledge and skills among Sungai Bilu residents in South Kalimantan for using riverbank plants as alternative medicine.

This study found that multi-walled carbon nanotubes promoted root hair growth in certain plants, with results indicating they modulate nitric oxide and ethylene pathways crucial to this development.

In this study, the bark of Spondias mombin showed potential anti-tumor effects in rats with induced cancer, reducing symptoms like hair loss and low food intake, but tachycardia was noted as a possible side effect.

This study reports that combining baricitinib with low-dose cyclosporine and steroids resulted in effective and safe treatment for a case of alopecia totalis, maintaining hair regrowth without adverse effects.

This article discusses the role of external beam radiotherapy as a primary treatment method for cancer and reports no new clinical findings.

Baricitinib helps regrow hair in teens with severe alopecia areata.

Antisense oligonucleotides show promise for treating Myotonic Dystrophy type I.

In this report, a female patient with ulcerative colitis, alopecia areata, and pyoderma gangrenosum showed improvement in all three conditions after being treated with tofacitinib.

This study found that a combination of betulin and cytostatic Namitecan had a statistically significant synergistic effect on solid Ehrlich adenocarcinoma tumors in NMRI mice, and suggests a promising method for administering betulin in in vivo experiments despite its water insolubility.

This study found that patients with the MITF p.E318K variant are more likely to develop multiple primary melanomas and dysplastic nevi with uncommon dermoscopic patterns compared to non-carriers.

This study observed that 61.3% of helmets from online motorcycle taxi passengers in the Stasiun Tugu Yogyakarta area were contaminated with dermatophyte fungi, with higher contamination risk in helmets used over five years or infrequently cleaned.

Baricitinib reduces inflammation and mitochondrial damage in skin cells.

This study found that additive discourse markers were the most frequently used type in a sampled news article from The Jakarta Post.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.